Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells $117,050.10 in Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) EVP Jason Daly sold 6,613 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $17.70, for a total transaction of $117,050.10. Following the sale, the executive vice president directly owned 245,171 shares in the company, valued at $4,339,526.70. This trade represents a 2.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Amneal Pharmaceuticals Stock Performance

Shares of Amneal Pharmaceuticals stock traded down $0.39 during trading hours on Thursday, reaching $17.27. The company’s stock had a trading volume of 2,244,096 shares, compared to its average volume of 2,168,140. Amneal Pharmaceuticals, Inc. has a one year low of $9.15 and a one year high of $19.26. The company’s 50 day simple moving average is $17.08 and its 200 day simple moving average is $14.54. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The stock has a market cap of $5.51 billion, a P/E ratio of 35.24 and a beta of 1.27.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AMRX. Artemis Investment Management LLP bought a new stake in Amneal Pharmaceuticals during the 4th quarter valued at $1,574,000. Louisiana State Employees Retirement System bought a new position in shares of Amneal Pharmaceuticals in the first quarter worth $936,000. Tudor Investment Corp ET AL bought a new position in shares of Amneal Pharmaceuticals in the third quarter worth $921,000. California State Teachers Retirement System increased its holdings in shares of Amneal Pharmaceuticals by 37.6% during the first quarter. California State Teachers Retirement System now owns 207,239 shares of the company’s stock valued at $2,576,000 after purchasing an additional 56,588 shares during the period. Finally, HighTower Advisors LLC bought a new stake in shares of Amneal Pharmaceuticals during the fourth quarter valued at about $1,121,000. Institutional investors own 31.82% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Weiss Ratings raised shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, July 29th. Barclays increased their price target on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. The Goldman Sachs Group reissued a “buy” rating and issued a $21.00 price target on shares of Amneal Pharmaceuticals in a report on Friday, July 31st. Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. Finally, UBS Group upped their price objective on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $17.67.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.